32nd week of 2010 patent applcation highlights part 49 |
Patent application number | Title | Published |
20100204205 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION - A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having histamine H1 receptor agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having histamine H1 receptor agonist activity. Methods of treatment and kits for administration are also provided. | 2010-08-12 |
20100204206 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them - Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | 2010-08-12 |
20100204207 | Compounds and Methods for Treating Dyslipidemia - Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed. | 2010-08-12 |
20100204208 | PROTEIN KINASE C INHIBITORS AND USES THEREOF - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2010-08-12 |
20100204209 | CCR2 Receptor Antagonists and Uses Thereof - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 2010-08-12 |
20100204210 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention relates to methods of treating pulmonary diseases in patients that beta adrenergic receptor agonist therapy is not effective. The method comprises the steps of: identifying a patient who suffers from a pulmonary disease and has reduced responsiveness to treatment with one or more beta adrenergic receptor agonists, and administering to the patient an effective amount of a Rho kinase inhibitor compound, wherein said pulmonary disease is selected from the group consisting of: asthma, chronic obstructive pulmonary disease, respiratory tract illness caused by respiratory syncytial virus infection such as RSV-induced wheezing, airway hyperreactivity, or bronchiolitis, bronchiectasis, alpha-1-antitrypsin deficiency, lymphangioleiomyomatosis, cystic fibrosis, bronchiolitis or wheezing caused by agents other than respiratory syncytial virus, chronic bronchitis, and occupational lung diseases. | 2010-08-12 |
20100204211 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES - The present invention relates to the use of indolinones of general formula | 2010-08-12 |
20100204212 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS - Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, | 2010-08-12 |
20100204213 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS - The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders. | 2010-08-12 |
20100204214 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF - Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein. | 2010-08-12 |
20100204215 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF - Novel 2,8-diaminophenothiazine compounds, a method for preparing the same, and uses of the novel 2,8-diaminophenothiazine compounds in the field of treating liquid or gaseous fluids, especially influents and industrial or domestic effluents. | 2010-08-12 |
20100204216 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION - The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on. | 2010-08-12 |
20100204217 | TREATMENT FOR LEUKEMIA AND IDIOPATHIC APLASTIC ANEMIA - A process for treating a patient with leukemia or an aplastic anemia having cells with inclusions that stain with anti- | 2010-08-12 |
20100204218 | FUSED BICYCLIC COMPOUND - The present invention provides a novel fused bicyclic compound having an affinity to a receptor of mineral corticoid (MR), shown by the formula [I]: | 2010-08-12 |
20100204219 | AROMATIC 1,4-DI-CARBOXYLAMIDES AND THEIR USE - The invention relates to novel compounds of formula (I) wherein X, Y, Z represent independently from one another C or N, n stands for 1, 2, 3, m is 0 or 1, p stands for 0 or an integer from 1 to 6, R | 2010-08-12 |
20100204220 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS - Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein. | 2010-08-12 |
20100204221 | Pyrrolopyrimidinyl axl kinase inhibitors - Compounds represented by Formula (I): | 2010-08-12 |
20100204222 | PYRIDOPYRIMIDINE DERIVATIVES AS P13 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using pyridopyrimidine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridopyrimidine derivatives. | 2010-08-12 |
20100204223 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof - The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved. | 2010-08-12 |
20100204224 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS - Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents; wherein (1) represents (A), (B) or (C); R | 2010-08-12 |
20100204225 | Organic compounds - There are provided according to the invention compounds of formula (I), in free or salt form, wherein R | 2010-08-12 |
20100204226 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS - Quinazolinone compounds of formula (I) are described, | 2010-08-12 |
20100204227 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE - Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases. | 2010-08-12 |
20100204228 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor - In one embodiment, compounds of the following structure are described, wherein R | 2010-08-12 |
20100204229 | FUNGICIDE HETEROCYCLYL-PYRIMIDINYL-AMINO DERIVATIVES - The present invention relates to heterocyclyl-pyrimidinyl-amino derivatives of formula (I) | 2010-08-12 |
20100204230 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS - Compounds of formula (I) selectively inhibit production of Aβ(1-42) and hence find use in treatment of Alzheimer's disease and other conditions associated with deposition of A(β) in the brain. | 2010-08-12 |
20100204231 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer. | 2010-08-12 |
20100204232 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE - The present invention relates to the xinafoate salt of N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine. This compound is a suitable drug substance and is useful in the treatment of conditions including asthma. | 2010-08-12 |
20100204233 | IMIDAZOLE DERIVATIVES - The invention relates to imidazole derivatives which have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. | 2010-08-12 |
20100204234 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases - The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof. | 2010-08-12 |
20100204235 | ORGANIC COMPOUNDS - Compounds of formula I | 2010-08-12 |
20100204236 | Substituted imidazoles as bombesin receptor subtype-3 modulators - Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. | 2010-08-12 |
20100204237 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase - Compounds of Formula (1), pharmaceuticals containing the same, especially anti-HIV agents having anti viral activity, especially inhibitory activity against HIV integrase, | 2010-08-12 |
20100204238 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like. | 2010-08-12 |
20100204240 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus - Provided are compounds of Formula (I): wherein R | 2010-08-12 |
20100204241 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES - Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4: | 2010-08-12 |
20100204242 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor - The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine | 2010-08-12 |
20100204243 | Process for the Preparation of Poly DL-Lactide-Co-Glycolide Nanoparticles Having Antitubercular Drugs Encapsulated Therein - A process for the preparation of Poly DL-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein comprising: (i) preparation of an aqueous solution of stable water soluble drugs in DW/NS/PBS (ii) preparation of unstable drugs in DW/NS/PBS (iii) preparation of a polymer and hydrophobic drug solution in an organic solvent, (iv) mixing separately the solutions of steps (i) and (ii) with that of step (iii) and sonicating under cold conditions, (v) adding the above emulsion to aqueous PVA and resonicating under cold conditions, (vi) stirring the emulsion 0nd centrifuging the same (vii) washing the said particles, reconstituting the same and lyophilizing. | 2010-08-12 |
20100204244 | AGENTS FOR TREATMENT OF DIABETIC RETINOPATHY AND DRUSEN FORMATION IN MACULAR DEGENERATION - Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof. | 2010-08-12 |
20100204245 | Amino-pyridines As Inhibitors Of Beta-secretase - The present invention provides an amino-pyridine compound of formula I | 2010-08-12 |
20100204246 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer. | 2010-08-12 |
20100204247 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. | 2010-08-12 |
20100204248 | MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING - Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds. | 2010-08-12 |
20100204249 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA - Niacin drugs are frequently utilized as a therapeutic to treat CVD, increase HDL levels, and/or decrease TG levels. As disclosed herein, it has been found that administration of one or more sPLA | 2010-08-12 |
20100204250 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions - The present invention relates to substituted xanthines of general formula | 2010-08-12 |
20100204251 | MOLECULAR TARGET OF NEUROTOXICITY - The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterisation and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention equally concerns methods for identifying or screening compounds active in these diseases. The invention further concerns the compounds, genes, cells, plasmids or compositions useful for implementing the hereinabove methods. In particular, the invention describes the role of PDE4B in these diseases and its use as a therapeutic, diagnostic or experimental target. | 2010-08-12 |
20100204252 | METHODS OF TREATING HYPERTENSION WITH AT LEAST ONE ANGIOTENSIN II RECEPTOR BLOCKER AND CHLORTHALIDONE - The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone. | 2010-08-12 |
20100204253 | Ribosome Structure and Protein Synthesis Inhibitors - The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism. | 2010-08-12 |
20100204254 | Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin - The present invention discloses statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) consistently and significantly increased endothelial cell thrombomodulin protein and functional activity. Statins also abrogated the downregulation of thrombomodulin that occurs in response to radiation injury. These results indicate that preserving or restoring endothelial thrombomodulin expression and function by statins may be useful in a variety of disorders associated with widespread endothelial dysfunction such as sepsis, adult respiratory distress syndrome, and normal tissue radiation injury. | 2010-08-12 |
20100204255 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS - The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2010-08-12 |
20100204256 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions. | 2010-08-12 |
20100204257 | SPIROINDOLINONE PYRIDINE DERIVATIVES - There are provided compounds of the formula | 2010-08-12 |
20100204258 | METHODS AND COMPOSITIONS FOR MODULATING INSULIN SECRETION AND GLUCOSE METABOLISM - The present invention relates to methods and compositions for treating or ameliorating the effects of diabetes. In addition, the present invention relates to methods and compositions for treating or preventing hyperglycemia, as well as modulating monoamine levels, islet β-cell insulin secretion, insulin and/or glucagon levels in a patient. In certain preferred embodiments, such methods include administering to a patient an effective amount of a vesicular monoamine transporter type 2 (VMAT2) antagonist, such as tetrabenazine (TBZ), dihydrotetrabenazine (DTBZ), tetrahydroberberine (THB), reserpine, emetine, Compound 6, or enantiomers, optical isomers, diastereomers, N-oxides, crystalline forms, hydrates, metabolites or pharmaceutically acceptable salts thereof. | 2010-08-12 |
20100204259 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL - The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. | 2010-08-12 |
20100204260 | Multi-Substituted Imidazolines And Method Of Use Thereof - A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium | 2010-08-12 |
20100204261 | MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN FOR TREATMENT OF BREAST, COLORECTAL, PANCREATIC, OVARIAN AND LUNG CANCERS - A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, | 2010-08-12 |
20100204262 | CATIONIC PHARMACEUTICALLY ACTIVE INGREDIENT CONTAINING COMPOSITION, AND METHODS FOR MANUFACTURING AND USING - A cationic pharmaceutically active ingredient containing composition is provided. The composition includes a cationic pharmaceutically active ingredient, a hydrophobic polymer/hydrophilic polymer adduct comprising a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups, a compatibilizing amount of a long chain organic acid having a carbon chain of at least 8 carbon atoms, and at least about 50 wt. % water. | 2010-08-12 |
20100204263 | METHOD OF TREATING MULTIDRUG RESISTANT CANCERS - A method of treating multidrug resistant cancers in a patient, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The values and preferred values for variables R1 and R2 are defined herein. | 2010-08-12 |
20100204264 | POLYMORPHIC FORM OF GRANISETRON BASE, METHODS FOR OBTAINING IT AND FORMULATION CONTAINING IT - Relates to a new polymorphic form of Granisetron base, Form I, to methods for obtaining thereof, to the method for obtaining Granisetron.HCl and its use for preparing pharmaceutical formulations. The Form I is characterized by the X-ray powder diffractogram shown in FIG. | 2010-08-12 |
20100204265 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections - Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV). | 2010-08-12 |
20100204266 | COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED POPULATIONS OF BIOAGENTS - The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of bacterial bioagents and populations of bioagents which are members of the | 2010-08-12 |
20100204267 | Preventive and therapeutic medicament for gastroesophageal reflux disease - The compound of the following formula: | 2010-08-12 |
20100204268 | PROCESSES FOR PREPARING DIFFERENT FORMS OF (S)-(+)-CLOPIDOGREL BISULFATE - The invention provides improved processes for the preparation of hydrated form of (S)-(+)-Clopidogrel bisulfate as well as improved processes for the preparation of form-I and form-II of (S)-(+)-Clopidogrel bisulfate. | 2010-08-12 |
20100204269 | Compounds and methods for treatment of chemotherapy-induced anemia - The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein. | 2010-08-12 |
20100204270 | Quinoline Derivatives as Antibacterial Agents - Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof. Several of these compounds are also claimed as such. Further the combination of the above compounds with other antibacterial agents is described | 2010-08-12 |
20100204271 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND - Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractometry. | 2010-08-12 |
20100204272 | Compounds which have activity at M1 receptor and their uses in medicine - Compounds of formula (I) or a salt thereof are provided: | 2010-08-12 |
20100204273 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors - Disclosed are methods for use of compounds of formula (I) in the treatment of CNS disorders such as dysthymia, schizophrenia, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, pain, and memory disorders: | 2010-08-12 |
20100204274 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of MIP-1α of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R | 2010-08-12 |
20100204275 | N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel N-piperidin-4-ylmethyl amide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2010-08-12 |
20100204276 | INDOLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2010-08-12 |
20100204277 | Compositions and Methods for Controlling Infestation - The present invention is directed to methods of treating pest infestation by inhibiting metabolic processes of the pest such as for example, processes involved in invertebrate remodelling. | 2010-08-12 |
20100204278 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment - The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included. | 2010-08-12 |
20100204279 | Therapeutic Salt Compositions and Methods - Therapeutic salt compositions and methods are disclosed herein. | 2010-08-12 |
20100204280 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE - A compound of Formula, (I) or Formula: (II) | 2010-08-12 |
20100204281 | ECTOPARASITE CONTROL METHOD - This invention relates to a method of controlling or preventing infestations of ectoparasites, preferably hematophageous ectoparasites, on an animal by administering to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, or an N-oxide, or a pharmaceutically or veterinarily acceptable salt thereof, | 2010-08-12 |
20100204282 | Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases. | 2010-08-12 |
20100204283 | PESTICIDE COMPOSITION POTENTIATED IN EFFICACY AND METHOD FOR POTENTIATING EFFICACY OF PESTICIDAL ACTIVE INGREDIENTS - The present invention provides a pesticide composition comprising a pesticidal active ingredient and a compound represented by chemical formula (I) or chemical formula (II) | 2010-08-12 |
20100204284 | HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS - Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever. | 2010-08-12 |
20100204285 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES - The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R | 2010-08-12 |
20100204286 | METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS - A method for moderating a gastrointestinal adverse effect induced by at least one cytotoxic agent, for example ionizing radiation and/or at least one chemotherapeutic agent, in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor or a compound selected from (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylaminol-4-methylpentanoic acid (ORE1001), pharmaceutically acceptable salts thereof and prodrugs thereof. A method for treating a cancerous condition in a subject comprises administering to the subject (a) at least one cytotoxic anticancer agent, for example ionizing radiation and/or at least one chemotherapeutic agent; and (b) an ACE2 inhibitor or a compound selected from ORE1001, pharmaceutically acceptable salts thereof and prodrugs thereof in an amount effective to moderate a gastrointestinal adverse effect induced by the anticancer agent. | 2010-08-12 |
20100204287 | HETEROCYCLIC AMIDE DERIVATIVES USEFUL AS MICROBIOCIDES - The invention relates to a fungicidally active compound of formula (I): | 2010-08-12 |
20100204288 | Heteroaryl-Ureas and Their Use as Glucokinase Activators - This invention relates to compounds of formula (I) | 2010-08-12 |
20100204289 | VISCOSE FIBER WITH MODIFIED PROPERTY AND A PROCESS FOR MAKING THEREFOR - A viscose fiber having property modifying constituents such as thermoregulatory activity, antimicrobial activity, and perfumed and a method of making thereof is disclosed. Micro-reservoirs are formed in the fibers having thermoregulatory activity, antimicrobial constituents, and perfumed constituents. | 2010-08-12 |
20100204290 | PROCEDURE FOR OPERATING A PARTICLE FILTER ARRANGED IN AN EXHAUST FUME AREA OF A BRENNKRAFTMASCHINE AND DEVICE TO EXECUTE THE PROCEDURE - A method of increasing the survival of animals and aquatic species susceptible to birnavirus infection by treating them before, during and/or after bimavirus exposure, with a chemical compound capable of inhibiting viral replication. A method of treating aquatic species to increase their survival in the presence of a virus, particularly an aquatic bimavirus, and to increase the yield of farmed fish susceptible to viral infection. The present invention provides methods for increasing survival of virally-exposed aquatic animals by administering therapeutically effective amounts of isoxazol compounds to aquatic animals susceptible to bimavirus infection and/or IPNV infection, particularly in fish such as salmonoid species, which are easily exposed to IPNV. The present invention also provides methods for increasing survival of virally-exposed animals by administering therapeutically effective amounts of isoxazol compounds to farmed animals susceptible to bimavirus infection and/or IBDV infection, particularly in poultry such as chickens, which are exposed to IBDV. | 2010-08-12 |
20100204291 | Method for Facilitating Extinction Training Using D-Cycloserine - Methods are disclosed for improving treatment of various medical conditions via administration of D-cycloserine to facilitate learning. Specifically, by administering D-cycloserine on a post-training pre-sleep basis, subsequent to extinction training during the day, the methods can improve upon the known ability of D-cycloserine to facilitate extinction learning. | 2010-08-12 |
20100204292 | Pharmaceutical compositions comprising intra-and extra-granular fractions - A pharmaceutical composition comprising i) an intra-granular fraction containing a pharmaceutically acceptable active component and a first excipient and ii) an extra-granular fraction containing a second excipient. The pharmaceutical composition is characterized by being substantially surfactant-free and by exhibiting a rapid-dissolution profile. | 2010-08-12 |
20100204293 | PHARMACEUTICAL COMPOSITION - Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1) below, 50-95% by mass of an alcohol, and 0.1-35% by mass of water and/or an anionic surfactant. | 2010-08-12 |
20100204294 | Methods For Assessing, Improving, Or Maintaining Urogenital Health in Postmenopausal Woman - This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health. | 2010-08-12 |
20100204295 | TREATMENT OF ALLERGIC DISEASE WITH IMMUNOMODULATOR COMPOUNDS - A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which composes an aromatic or heterocyclic amino acid residue or a derivative thereof. Preferably, the immunomodulatory compound is a dipeptide which comprises a D- or L-tryptophan residue. | 2010-08-12 |
20100204296 | Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt - The present invention provides a novel and stable amorphous form of darifenacin free base, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a novel and stable polymorphic form of darifenacin hydrobromide, process for preparation, pharmaceutical compositions, and method of treating thereof. | 2010-08-12 |
20100204297 | INFLUENZA THERAPEUTIC - The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention. | 2010-08-12 |
20100204298 | Use of Antisense Oligonucleotides Against CPLA2 in the Treatment of Cancer - Inhibitors of cPLA | 2010-08-12 |
20100204299 | C-CBL AND ANTAGONISTS THEREOF FOR THE TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to the treatment of cancer. More specifically, the present invention relates to the use of c-cbl as a marker for the diagnosis and/or prognosis of cancer, and to the use of a c-cbl antagonist for the treatment of a cancer associated with resistance to apoptosis. | 2010-08-12 |
20100204300 | ANTI-VIRAL METHODS AND COMPOSITIONS - The instant disclosure relates to methods and compositions for silencing poxvirus gene expression and replication using RNA interference. In certain embodiments, the disclosure relates to methods of treating a subject with a poxvirus infection. | 2010-08-12 |
20100204301 | Reducible polymers for nonviral gene delivery - Provided herein are biodegradable copolymers and nanoplex delivery systems comprising the same and a cargo molecule, such as a nucleic acid, a polynucleotide or other biomolecule. The biodegradable copolymers may comprise a reducible polymer linearly modified with lysine, such as a linear lysine-modified N,N′-cystamine bisacrylamide. The biodegradable copolymers also may be conjugated to a sequestering moiety, such as dietheylamine. The biodegradable copolymers also may comprise one or both of a targeting moiety and one or more moieties to facilitate endosomal escape. Also provided are methods for treating a pathophysiological condition and for increasing biocompatibility of a polymeric delivery system upon delivery to a subject using the biodegradable copolymers and nanoplexes. | 2010-08-12 |
20100204302 | SIDNA AGAINST HEPATITIS C VIRUS (HCV) - Silencing of HCV RNA can be achieved by siDNA. These are oligodeoxynucleotides consisting of an antisense strand homologous to the viral RNA and a second strand, partially complementary to the antisense-strand. The two strands are preferentially linked by a linker (eg 4 thymidines). Triple-helix formation is a preferred effect. The siDNA is superior to siRNA because the formation of RNA-DNA hybrids is preferred over double-stranded DNA or double-stranded RNA, which forms as tertiary structures in RNA genomes. Also the induction of interferon is less likely. siDNA is easier to synthesize and it is more stable. It can be combined with siRNA. | 2010-08-12 |
20100204303 | Pharmaceutical Compositions for Administering Oligonucleotides - The invention relates to pharmaceutical compositions useful for administering an oligonucleotide to an animal in need thereof. The pharmaceutical compositions include nano-particles or micro-particles of (i) a protonated oligonucleotide and (ii) a pharmaceutically acceptable organic base or include nano-particles or micro-particles of (i) an oligonucleotide and (ii) a divalent metal ion. | 2010-08-12 |
20100204304 | NOGO Receptor Binding Protein - The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof. | 2010-08-12 |
20100204305 | SMALL INTERFERING RNA MOLECULES AGAINST RIBONUCLEOTIDE REDUCTASE AND USES THEREOF - Small interfering RNA (siRNA) molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene are provided. The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be used to attenuate the growth and/or metastasis of various types of mammalian cancers. | 2010-08-12 |